Eyelash Serums in Panama: When a Cosmetic Is a Drug

Eyelash serums in Panama: where the cosmetic ends and the drug begins

In Panama, products sold as "eyelash serum" promise longer, thicker, darker lashes. Some work because they contain a prostaglandin analog: the same molecular family as glaucoma eye drops. That is the line between a cosmetic and a drug, and it is the line the FDA drew in 2007 and 2011¹². This piece recommends no product: it reviews what is documented for physicians who see patients using these serums.

Bimatoprost was approved in the United States in December 2008 to treat eyelash hypotrichosis, after first being a drug to lower intraocular pressure⁸⁴. Its effect on lashes is real: it raises the share of follicles in anagen and stimulates melanogenesis, which explains longer, darker lashes⁸.

What the FDA did: the 2007 seizure and the 2011 warning letters

On November 19, 2007, U.S. Marshals seized, at the FDA's request, 12,682 applicator tubes of Age Intervention Eyelash, sold by Jan Marini Skin Research (San Jose, California), with a sales value of about $2 million¹. The FDA considered it an "unapproved and misbranded drug" because it was promoted for eyelash growth, and an adulterated cosmetic because it contained bimatoprost, the active ingredient of a drug approved for elevated intraocular pressure¹. The risks cited included decreased vision, macular edema and uveitis; for people also using prescription bimatoprost, possible optic nerve damage¹.

On April 18, 2011 the FDA (Los Angeles District, letter W/L 32-11) wrote to Lifetech Resources about RapidLash, NeuLash and NeuveauBrow, which contained isopropyl cloprostenate. The letter describes it as a synthetic prostaglandin analog and states that "Prostaglandin analogs are well known to have an effect on the structure or function of the body"; the products were therefore treated as unapproved new drugs². It also objected to claims of "Safety Status in the US and EU – Passed," misleading because the ingredient's risks were not disclosed². A note on rigor: the copy of that letter we could open is a reproduction on a blog of FDA letters, not the agency's own page².

Bimatoprost efficacy for lashes and what the trials say

The pivotal trial (137 subjects on bimatoprost, 141 on vehicle) found at least a one-grade improvement on the global eyelash scale in 78.1% versus 18.4% at week 16; only conjunctival hyperemia was significantly more frequent with the drug⁷. A pooled analysis of six trials (680 exposed) described mostly mild, local events that were reversible on stopping⁹. A 12-month follow-up trial maintained efficacy¹⁰, and a retrospective review of 585 patients averaging about 19 months of use found few documented events and no iris hyperpigmentation¹¹.

Read those data with caution. A 2021 review concluded that the literature is dominated by industry-sponsored trials and that study design may have underreported application discomfort and periorbitopathy; the risk of increased iris pigmentation remains inadequately investigated¹². Several of the earlier studies have authors employed by the manufacturer⁹¹¹.

Ocular risks of bimatoprost and other analogs: what the physician should look for

• Iris: the approved product's label warns of increased brown iris pigmentation, "likely to be permanent," which may not be noticeable for months or years³. The glaucoma eye-drop version warns that pigmentation increases for as long as it is administered⁴.
• Lid and orbit: the label describes periorbital darkening, generally reversible on stopping, and among postmarketing reactions periorbital changes with fat atrophy, deepening of the eyelid sulcus and ptosis³.
• Intraocular pressure: in patients already using prostaglandin analogs to lower pressure, concomitant use may interfere with the desired effect and calls for consultation and monitoring³.
• Contamination: the label warns of bacterial keratitis with contaminated multiple-dose containers and calls for sterile single-use applicators³. A bottle with no quality control offers no such assurance.
• Pregnancy: labeling of ophthalmic analogs includes caution in pregnancy; the 2011 FDA letter mentions Pregnancy Category C².

In glaucoma, prostaglandin-associated periorbitopathy was seen in 93.3% of bimatoprost users, 41.4% of latanoprost and 70% of travoprost in a series of 105 patients, with periorbital fat loss the first sign¹⁴. That figure reflects eye-drop dosing, not a serum. But an assessment of manufacturers' "before-and-after" photos for serums containing analogs (bimatoprost, isopropyl cloprostenate and others) found higher volume-loss scores than for serums without analogs or false lashes, and notes that the customer-facing ingredient list often does not mention the prostaglandin¹³. There are also cases: periocular discoloration with an isopropyl cloprostenate serum that remitted on stopping¹⁵.

Law 419 in Panama: sanitary registration for cosmetics versus medicines

Law 419 of 2024 defines a cosmetic as a topical product for the body's superficial parts "to clean, perfume, change their appearance, protect them or keep them in good condition" (art. 3, no. 22) and requires sanitary registration to import, distribute and sell it (art. 56), valid for ten years (art. 57)⁵. A medicine is defined by function: preventing, diagnosing or treating disease, or modifying physiological systems (art. 3, no. 53)⁵. Competence over the truthfulness of advertising is shared by the Dirección Nacional de Farmacia y Drogas (DNFD) and ACODECO (art. 10)⁵.

A prudent reading: the text of the law we reviewed sets no general test to tell a cosmetic from a medicine beyond those definitions, and we could not read the whole law⁵. A serum that alters a physiological system through a pharmacologic active ingredient hardly fits the cosmetic definition and its pathway would be that of a medicine, but the health authority decides case by case. We found no Minsa or DNFD alert specific to eyelash serums or bimatoprost, nor did we verify whether any product of this type is registered in Panama.

There is DNFD precedent on undeclared ingredients: on July 23, 2026 it warned in Panama about Artri Ajo Rey and Artri Ajo King, which have no sanitary registration⁶. For the local framework see Artri Ajo Rey in Panama, the double standard in sanitary registration for aesthetics, miracle shampoos, Botox in a cream and GHK-Cu creams.

What to ask in the clinic if a patient uses an eyelash serum

• Ask for the label. Look for bimatoprost, isopropyl cloprostenate, norbimatoprost and other analog names; the ingredient list may not mention the prostaglandin¹³.
• Examine. Iris color change, eyelid darkening, a deeper lid sulcus, ptosis, hyperemia or itching justify stopping and referral³¹³¹⁵.
• With glaucoma or pressure-lowering drops, coordinate with ophthalmology before the patient uses any analog on the eyelid³.
• Report. Adverse events from unregistered products can be reported to the national system; see pharmacovigilance in Panama with VigiMedic.